Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform

Tormey, Christopher A.; Peddinghaus, Marie E.; Erickson, Michelle L.; King, Karen E.; Cushing, Melissa M.; Bill, Jerry; Goodrich, Tay; Snyder, Edward L.

doi:10.1111/j.1537-2995.2009.02412.x

Cited by 33 publications

(68 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The superior efficacy of the Spectra Optia TPE protocol over the COBE Spectra system has previously been demonstrated in a nonblinded, randomized, crossover comparative clinical study [2]. The positive results were confirmed later in several single arm usability studies with a total of >150 procedures.…”

mentioning

confidence: 76%

“…Dual needle continous flow has inherently higher average inlet flow rates than single needle intermittent and therefore shorter procedure times. The double needle procedure may however not solely explain the more rapid TPE procedure with Spectra Optia, as the Optia system was also proven to be faster than COBE Spectra [2,3]. A shorter procedure time is particularly appreciable for chronically ill patients who will spend less time per procedure, and for young and working patients who report an increase in quality of life [20].…”

Section: Discussionmentioning

confidence: 99%

“…The positive results were confirmed later in several single arm usability studies with a total of >150 procedures. Among the advantages of the Spectra Optia system, its documented higher plasma exchange efficiency and lower PLT loss have been most notable [2][3][4][5][6][7].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+

Lambert¹,

Gericke²,

Smith³

et al. 2010

J. Clin. Apheresis

View full text Add to dashboard Cite

For therapeutic plasma exchange (TPE), continuous and intermittent flow separators are known to be efficient. This study was undertaken to compare the performances of the Spectra Optia, a continuous flow centrifugal apheresis system recently developed by CaridianBCT, with the Haemonetics Multicomponents System (MCS)+ apheresis system based on intermittent flow centrifugation. The primary objective of the study was to compare the time required to exchange one total plasma volume with both separators. The secondary objectives were to determine the plasma exchange efficiency, the plasma extraction rate, the percentage of target exchange volume achieved, and the loss of cellular components. The study involved prospectively paired comparison of 16 TPE on each device performed in patients with chronic diseases treated with TPE. The time required to exchange 1 total plasma volume was 182 ± 36 minutes for MCS+ procedures and 100 ± 20 minutes for the Spectra Optia procedures (P < 0.05, all results presented as mean ± standard deviation). A significantly higher plasma extraction rate was achieved (30.2 ± 4.3 vs 16.8 ± 3.4 mL/min, respectively, P < 0.05), and the plasma exchange efficiency was slightly better with the Spectra Optia compared with the MCS+ procedures (83.4 ± 7.0 vs 80.0 ± 8.5%, P < 0.05). The platelet loss was significantly lower with the Spectra Optia compared with the MCS+ procedures (1.6 ± 2.3 vs 7.5 ± 4.2%, respectively, P < 0.05), whereas the red blood cells loss was comparable. In conclusion, the Spectra Optia has significantly higher extraction rate and exchange efficiency than the MCS+ allowing to remove the same amount of plasma in less time, by processing less blood. It also removes significantly less platelets than the MCS+ separator.

show abstract

mentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+

Lambert¹,

Gericke²,

Smith³

et al. 2010

J. Clin. Apheresis

View full text Add to dashboard Cite

show abstract

“…13 Moreover, Tormey et al have demonstrated higher plasma removal efficiency for Optia in comparison to the Cobe. 16 At first, we did not consider increased plasma efficiency when the devices were switched for SPD procedures. Rather than focusing on inlet flow, the Optia SPD software can be conveniently programmed to cap the plasma pump flow rate automatically, if necessary.…”

Section: Discussionmentioning

confidence: 99%

Spectra Optia apheresis system: experience with secondary plasma devices

Rummler¹,

Volkholz²,

Steinke³

et al. 2017

IJCTM

View full text Add to dashboard Cite

Abstract:Performing clinical procedures and optimal management of Spectra Optia in combination with secondary plasma devices (SPDs) have not been described in the literature. To contribute to this topic, we examined 300 data log files from patients treated with the Spectra Optia from November 2015 until October 2016. Of these 300 procedures, 149 secondary plasma treatments were conducted in 13 patients (76 immunoadsorption [IA] and 73 lipoprotein apheresis [LA]). Nine patients had IA due to transplantation and autoimmune diseases. Four patients were treated with LA after heart transplantation. Of the procedures, 62% were performed using peripheral venous access, even in patients with a low inlet blood flow. A central catheter was required only in 15% cases, and an arteriovenous fistula in 23% of the procedures. Anticoagulation management differed in both procedures. The LA procedures required a higher amount of citrate as they were performed using only citrate. The IA procedures required less citrate because a mixture of citrate and heparin was used. We did not observe clotting or bleeding, regardless of heparin use. Due to strict calcium management, no patient showed signs of hypocalcemia. Despite our apheresis management, four procedures had to be canceled preliminarily due to patient complications. The targeted substances could be reduced significantly: lipoprotein (a) (Lpa) level by 68% (76%-45%), low-density lipoprotein-cholesterol by 57% (64%-37%), and IgG from 6.6 (1.09-21.0) to 2.61 (0.33-14.7) g/l. The Cobe could be replaced by the Optia system effectively. The Optia has a high plasma extraction efficiency, which allows SPD procedures with peripheral venous access and moderate inlet flow rates.

show abstract

“…More modern systems now have continuous control over the interface in a continuously flowing system. This reduces cellular loss and maximizes the efficiency of plasma removal [16]. Double-filtration plasmapheresis [17] aims to reduce the loss of the lower molecular weight molecules otherwise lost in the filtration process, returning them to the patient.…”

Section: Method: Centrifugation or Filtration?mentioning

confidence: 99%

Role of therapeutic plasmapheresis in ANCA-associated vasculitis

Walters

2015

Pediatr Nephrol

View full text Add to dashboard Cite

show abstract

Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform

Abstract: The SPO has improved performance characteristics over the CSP. Based on our results, the SPO is acceptable for use in therapeutic plasma exchange programs.

Cited by 33 publications

References 14 publications

Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+

Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+

Spectra Optia apheresis system: experience with secondary plasma devices

Role of therapeutic plasmapheresis in ANCA-associated vasculitis

Contact Info

Product

Resources

About